Literature DB >> 9864973

Description and valuation of health-related quality of life among the general public in Japan by the EuroQol.

A Hisashige1, H Mikasa, T Katayama.   

Abstract

OBJECTIVE: Health-related quality of life plays an important role in assessing the effectiveness of health care. The EuroQol is a generic instrument for describing and valuing health-related quality of life. To elicit health state descriptions and their preferences among the general public in Japan and compare them with cross-national data, a feasibility study for applying the EuroQol to the general public in Japan was carried out. SUBJECTS AND METHODS: The subjects were 120 people aged 40s-60s randomly selected in a suburban area at Aichi Prefecture in Japan. In assessing health states and their preferences, the EuroQol valuation instrument (version 12, 1991) translated into Japanese was used. The questionnaires were distributed and collected by public health nurses. The valid responses (rate) were 89 (74%).
RESULTS: The mean scores (raw scores) using the visual analogue scale (VAS) for one's own health was 89.2. No statistically significant difference in VAS scores was observed for both sex and age. The contribution ratio of own health status, sex and age was 0.326 (p < 0.0001). The main independent variables were three dimensions of health status. Valuations for core health states varied from 96.3 (no problem in each health status) to 6.8 (dead). These VAS scores in Japan were correlated with those from other countries (p < 0.001). A multivariate analysis indicated that bias from own health status on preference valuations for core health states was not observed.
CONCLUSION: The health states and their preferences among the general public in Japan were estimated by using the EuroQol. The results show the feasibility of evaluation for health states quantitatively. Moreover, this study suggested cross-national and cross-cultural applicability of the EuroQol.

Entities:  

Mesh:

Year:  1998        PMID: 9864973

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  8 in total

1.  Construct validity of the EQ-5D in low-income Chinese American primary care patients.

Authors:  Erica I Lubetkin; Haomiao Jia; Marthe R Gold
Journal:  Qual Life Res       Date:  2004-10       Impact factor: 4.147

2.  Opposite poles: A comparison between two Spanish regions in health-related quality of life, with implications for health policy.

Authors:  Juan Oliva-Moreno; Néboa Zozaya; Beatriz G López-Valcárcel
Journal:  BMC Public Health       Date:  2010-09-26       Impact factor: 3.295

3.  Lead versus lag-time trade-off variants: does it make any difference?

Authors:  Federico Augustovski; Lucila Rey-Ares; Vilma Irazola; Mark Oppe; Nancy J Devlin
Journal:  Eur J Health Econ       Date:  2013-07

4.  Health related quality of life of Canary Island citizens.

Authors:  Juan Oliva-Moreno; Julio Lopez-Bastida; Melany Worbes-Cerezo; Pedro Serrano-Aguilar
Journal:  BMC Public Health       Date:  2010-11-05       Impact factor: 3.295

5.  Determinants of health-related quality of life in Iranian adults: evidence from a cross-sectional study.

Authors:  Satar Rezaei; Mohammad Hajizadeh; Ali Kazemi; Masoud Khosravipour; Farid Khosravi; Shahab Rezaeian
Journal:  Epidemiol Health       Date:  2017-08-15

Review 6.  Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review.

Authors:  Xinyu Qian; Rachel Lee-Yin Tan; Ling-Hsiang Chuang; Nan Luo
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

7.  Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.

Authors:  Yukari Okubo; Hitomi Morishima; Richuan Zheng; Tadashi Terui
Journal:  J Dermatol       Date:  2021-08-28       Impact factor: 3.468

8.  Depression and Its Association with Health-Related Quality of Life in Postmenopausal Women in Korea.

Authors:  Hyejin Park; Kisok Kim
Journal:  Int J Environ Res Public Health       Date:  2018-10-23       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.